What does this research mean for the field?

Ocrelizumab therapy over 12 months significantly reduces relapse rates and MRI lesion burden while improving disability scores in Indian patients with multiple sclerosis. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the real-world clinical effectiveness, radiological response, and safety profile of ocrelizumab over 12 months of therapy in patients with multiple sclerosis.

August 22, 2026Annals of Indian Academy of NeurologyOpen Access

A Retrospective, Single-Arm, Observational Study in Patients with Multiple Sclerosis in India Receiving Ocrelizumab Therapy for 1 Year

View Full Paper

Ask AI

Bookmark

Authors

MSMV Padma Srivastava JMJoy Dev Mukherji ARAnshu Rohatgi

Discussion

Member takes

Overview

Retrospective observational study demonstrates significant reductions in relapses and brain lesions in multiple sclerosis patients, suggesting favorable real-world therapeutic efficacy.

Key Points

To evaluate the real-world clinical effectiveness, radiological response, and safety profile of ocrelizumab over 12 months of therapy in patients with multiple sclerosis.
Retrospective, single-arm observational study in India of adults (N=55; mean age 38.2 [8.75] years; 61.8% female) diagnosed with multiple sclerosis receiving ocrelizumab for at least 12 months.
Evaluated primary outcomes of disability progression (Expanded Disability Status Scale [EDSS]) and annualized relapse rate, alongside secondary outcomes of MRI lesion counts and adverse safety events.
EDSS scores improved significantly from 3.77 (1.71) at baseline to 3.28 (2.05) at 12 months (P < 0.001), while annualized relapse rates decreased from 0.60 to 0.15.
MRI lesion burden was significantly reduced, with T2 lesions decreasing from 17.06 (12.94) to 1.09 (2.38) (P < 0.001) and gadolinium-enhancing T1 lesions from 1.26 (1.17) to 0.06 (0.23) (P < 0.001).
MS-related hospitalizations decreased from 32.7% pre-treatment to 0% at follow-up, with zero serious adverse events and 96.4% of patients experiencing no adverse events.

Cite This Study

Srivastava et al. (2026) studied this question.

synapsesocial.com/papers/6a895f53ca7ade938187dd03 https://doi.org/10.4103/aian.aian_165_26

View Full Paper

Ask AI

Bookmark

August 22, 2026Annals of Indian Academy of NeurologyOpen Access

A Retrospective, Single-Arm, Observational Study in Patients with Multiple Sclerosis in India Receiving Ocrelizumab Therapy for 1 Year

View Full Paper

Ask AI

Bookmark

Authors

MSMV Padma Srivastava JMJoy Dev Mukherji ARAnshu Rohatgi

Discussion

Member takes

Overview

Retrospective observational study demonstrates significant reductions in relapses and brain lesions in multiple sclerosis patients, suggesting favorable real-world therapeutic efficacy.

Key Points

To evaluate the real-world clinical effectiveness, radiological response, and safety profile of ocrelizumab over 12 months of therapy in patients with multiple sclerosis.
Retrospective, single-arm observational study in India of adults (N=55; mean age 38.2 [8.75] years; 61.8% female) diagnosed with multiple sclerosis receiving ocrelizumab for at least 12 months.
Evaluated primary outcomes of disability progression (Expanded Disability Status Scale [EDSS]) and annualized relapse rate, alongside secondary outcomes of MRI lesion counts and adverse safety events.
EDSS scores improved significantly from 3.77 (1.71) at baseline to 3.28 (2.05) at 12 months (P < 0.001), while annualized relapse rates decreased from 0.60 to 0.15.
MRI lesion burden was significantly reduced, with T2 lesions decreasing from 17.06 (12.94) to 1.09 (2.38) (P < 0.001) and gadolinium-enhancing T1 lesions from 1.26 (1.17) to 0.06 (0.23) (P < 0.001).
MS-related hospitalizations decreased from 32.7% pre-treatment to 0% at follow-up, with zero serious adverse events and 96.4% of patients experiencing no adverse events.

Cite This Study

Srivastava et al. (2026) studied this question.

synapsesocial.com/papers/6a895f53ca7ade938187dd03 https://doi.org/10.4103/aian.aian_165_26

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark